GN-CORPORATION
12.10.2021 08:37:04 CEST | Business Wire | Press release
Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study. Immune parameters like ratios of neutrophil to lymphocyte (NLR ), lymphocyte to c-reactive protein (LCR ) and leucocyte to c-reactive protein (LeCR ) were advantageous, along with CD4 and CD8 levels, in those who consumed Nichi Glucans than, those who didn’t, as published in Biomedicine and Pharmacotherapy, a peer reviewed journal (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005726/en/
The Covid-19 infection by SARS-COV-2 virus leads to several complications and those have succumbed to the illness developed cytokine storm because of an overreacting immune system, that should be tackled with immunomodulation. According to Dr Raghavan, the first author of the publication, the AFO-202 strain of Black Yeast Aureobasidium Pullulans produced Nichi-Glucan enhances the immune system, while the N-163 strain produced Nichi-Glucan REFIX, efficiently modulates immunity, avoiding any catastrophe. Their combination has yielded this encouraging outcome and our interpretations are based on the present study as well as pre-clinical and clinical studies in healthy volunteers, he added (https://doi.org/10.1101/2021.08.05.21261640 ).
Criteria such as NLR, LCR and LeCR have recently gained significance in assessing Covid-19 severity, which we have documented to be advantageous with Nichi Glucan consumption in healthy people and pre-clinically as well (https://www.researchsquare.com/article/rs-771315/v1 ). Having been proven to handle the immune system in a balanced manner and with potentials of Beta glucans to act through microglia of the brain (Journal of the neurological sciences; https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ), the Nichi glucan variants, with a safety track record of more than two decades may help tackle long Covid-19 also, concludes the study.
In the 1980s, evolution inspired, Prof Noboru Fujii started exploring this poly-extremo tolerant fungus, that was nature gifted . Positioned in the tree of life between animal and plant kingdom, the R&D team believes that the symbiosis of this prebiotic product with gut microbiome may unravel the mechanisms behind its multiple beneficial effects to human health.
GN Corporation, holding the exclusive global distribution rights of the Nichi Glucans, are pursuing elaborate research in bringing out the hidden potentials of several strains of this black yeast fungi produce and plan to undertake larger studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005726/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom